Etrasimod Significantly Improves Atopic Dermatitis in Phase 2b Trial
Etrasimod, an investigational drug for moderate to severe atopic dermatitis, demonstrated statistically significant improvements in a phase 2b clinical trial, according to a study presented at AAD VMX 2021.
New Research Sheds Light on Why Eczema So Often Begins in Childhood
Feb 25, 2026 View All Press Releases
Mount Sinai Dermatologists Use Tape Strips to Map Immune Changes in Common Skin Disease
Jun 10, 2025 View All Press Releases
Mount Sinai Experts Author Landmark ‘Seminar’ on Atopic Dermatitis (Eczema) in The Lancet
Feb 13, 2025 View All Press Releases